Literature DB >> 17001673

Transcriptome profiling in clinical breast cancer: from 3D culture models to prognostic signatures.

Marcia V Fournier1, Katherine J Martin.   

Abstract

Early detection has been one of the most effective strategies to control the growing cancer burden. The power of earlier detection has been demonstrated by the impact of pap-smear, mammography, and PSA tests on cancer patient treatment and survival. These tests benefit patients independent of their genetic background or race. However, in many cases, we are still losing the battle against cancer because patients that initially presented with low-grade disease progress rapidly to aggressive forms of the disease. As of yet, we have limited means to predict a particular patient's fate or to specifically treat subtypes of cancer. A combination of earlier detection and targeted therapy, based on information from transcriptome analysis, could be a powerful ally in this battle. The theme of this review article is to briefly summarize innovative strategies using three-dimensional (3D) cell cultures of human mammary epithelial cells to predict clinical outcome in breast cancer. This strategy has the potential to further enhance our understanding of breast cancer biology and to contribute to the identification of biologically significant bio-markers that are also useful drug targets. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001673     DOI: 10.1002/jcp.20787

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Modelling tissues in 3D: the next future of pharmaco-toxicology and food research?

Authors:  Giovanna Mazzoleni; D Di Lorenzo; N Steimberg
Journal:  Genes Nutr       Date:  2008-12-18       Impact factor: 5.523

2.  Theranostics for Breast Cancer Stem Cells.

Authors:  Woo Kyung Moon; Hoe Suk Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  A novel in vitro three-dimensional skeletal muscle model.

Authors:  Michele L Marquette; Diane Byerly; Marguerite Sognier
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-09-05       Impact factor: 2.416

Review 4.  Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling.

Authors:  Dana M Brantley-Sieders
Journal:  Semin Cell Dev Biol       Date:  2011-10-21       Impact factor: 7.727

5.  Comprehensive analysis of signal transduction in three-dimensional ECM-based tumor cell cultures.

Authors:  Iris Eke; Stephanie Hehlgans; Yaping Zong; Nils Cordes
Journal:  J Biol Methods       Date:  2015-11-17

6.  Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets.

Authors:  Germana Rappa; Javier Mercapide; Fabio Anzanello; Lina Prasmickaite; Yaguang Xi; Jingfang Ju; Oystein Fodstad; Aurelio Lorico
Journal:  Exp Cell Res       Date:  2008-03-20       Impact factor: 3.905

7.  Phenotypic heterogeneity of breast cancer stem cells.

Authors:  Aurelio Lorico; Germana Rappa
Journal:  J Oncol       Date:  2011-01-17       Impact factor: 4.375

8.  Gene and miRNA expression signature of Lewis lung carcinoma LLC1 cells in extracellular matrix enriched microenvironment.

Authors:  Vaidotas Stankevicius; Gintautas Vasauskas; Danute Bulotiene; Stase Butkyte; Sonata Jarmalaite; Ricardas Rotomskis; Kestutis Suziedelis
Journal:  BMC Cancer       Date:  2016-10-11       Impact factor: 4.430

9.  Large-scale pharmacological profiling of 3D tumor models of cancer cells.

Authors:  Lesley A Mathews Griner; Xiaohu Zhang; Rajarshi Guha; Crystal McKnight; Ian S Goldlust; Madhu Lal-Nag; Kelli Wilson; Sam Michael; Steve Titus; Paul Shinn; Craig J Thomas; Marc Ferrer
Journal:  Cell Death Dis       Date:  2016-12-01       Impact factor: 8.469

10.  3D matrix-based cell cultures: Automated analysis of tumor cell survival and proliferation.

Authors:  Iris Eke; Stephanie Hehlgans; Veit Sandfort; Nils Cordes
Journal:  Int J Oncol       Date:  2015-11-04       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.